Objective ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present business innovation project with the overall objectives of (1) marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) and other causes of cognitive decline based on the detection of amyloid-β biomarker in the brain using three 18F-labelled tracers recently approved by FDA and EMEA (Florbetapir, Florbetaben, and Flutemetamol) for their clinical use, and (2) validating the clinical performance of this new diagnostic medical device. This new brain-dedicated PET system, targeted to Mental Disorder Units and Nuclear Medicine Units of hospitals in Europe, USA and Japan, is unique in the market and offers several advantages compared to the whole-body PET systems, such as higher resolution, three times higher sensibility, a competitive price (up to three times lower), need of smaller hospital facilities, and lower radiotracer dose to the patient that leads to a lesser cost to the healthcare system. Due to these improved characteristics, the new brain-dedicated PET system will allow an early detection of AD and other causes of cognitive decline and to use this business opportunity to ensure profitability and growth of ONCOVISION. A Phase 1 project was previously funded and implemented (Call: H2020-SMEINST-1-2014; Cut-off date: 18th June, 2014; Topic: PHC-12-2014/2015 Clinical research for the validation of biomarkers and/or diagnostic medical devices; Proposal number: 651145). The feasibility study prepared in Phase 1 has verified the technological as well as economic viability of the product and its clinical validation. During Phase 2 the validation of clinical performance of the product will be carried out, to enable commercialisation in Phase 3. Fields of science medical and health sciencesbasic medicineneurologyepilepsymedical and health scienceshealth sciencespublic healthmedical and health sciencesbasic medicineneurologydementiaalzheimermedical and health sciencesclinical medicinepsychiatrymedical and health sciencesclinical medicineradiologynuclear medicine Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-2-2015 Funding Scheme SME-2 - SME instrument phase 2 Coordinator GENERAL EQUIPMENT FOR MEDICAL IMAGING SA Net EU contribution € 4 393 596,25 Address CALLE JERONIMO DE MONSORIU, NUM. 92 PLANTA BJ, PUERTA IZQ 46022 Valencia Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Este Comunitat Valenciana Valencia/València Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 4 393 596,25